Press release
Wet Age-Related Macular Degeneration Market Outlook 2034 - Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight
Wet Age-Related Macular Degeneration Market
Wet Age-Related Macular Degeneration Market Insights (7MM, 2023):
• Total Wet AMD market size: USD 7,783 million.
• United States: ~33% share, highest Wet Age-Related Macular Degeneration market size.
• Europe: Germany Wet AMD Market leads (~USD 1,313 million), Spain lowest Wet Age-Related Macular Degeneration Market size among European countries (~USD 353 million).
• Japan Wet Age-Related Macular Degeneration Market: Significant share in prevalence and treatment adoption.
Download the Full Wet AMD Market Report to Access Comprehensive Insights (2020-2034) - https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Wet Age-Related Macular Degeneration Future Outlook:
• Market growth expected with new therapies: OPT-302 (Opthea), KSI-501 (Kodiak Sciences), RGX-314 (Regenxbio) and others.
• Increasing prevalence and innovative long-acting treatments will expand the Wet AMD market size in the coming years.
Wet Age-Related Macular Degeneration Market Overview
Wet Age-Related Macular Degeneration (Wet AMD) is a progressive retinal disease caused by abnormal growth of blood vessels beneath the retina, often leading to vision loss. With an aging population globally, Wet AMD prevalence is rising rapidly. DelveInsight's analysis highlights a significant unmet need, despite advancements in anti-VEGF therapies and new gene-based treatments under clinical evaluation.
The Wet Age-Related Macular Degeneration treatment market is projected to grow considerably during the forecast period (2020-2034), driven by:
• Increasing patient pool due to aging demographics.
• Pipeline breakthroughs with gene therapies and long-acting biologics.
• Strategic regulatory approvals by EMA, FDA, PMDA, and NICE.
• Market expansion in 7MM supported by healthcare policy reforms and R&D investments.
Key Wet Age-Related Macular Degeneration Epidemiology Insights
DelveInsight's epidemiological assessment reveals striking figures that underscore the future potential of the Wet AMD market:
• The total diagnosed prevalent cases of AMD across the seven major markets (7MM) reached nearly 40 million in 2023.
• The United States accounted for the highest share with approximately 14 million cases in 2023, followed by Japan (~8 million) and Germany (~6 million).
• Within Europe, Germany had the highest Wet AMD prevalence (~595,000), while Spain reported the lowest (~160,000).
• Japan's Wet AMD prevalence reached ~840,000 cases in 2023, representing nearly 21% of the 7MM burden.
• Age-specific segmentation indicated that in the US, patients aged 70-79 years had the highest prevalence (~407,000 cases in 2023).
• The analysis highlights that Dry AMD remains more common in Japan (90% of total cases) compared to Wet AMD (10%).
These data illustrate not only the size of the existing burden but also the potential for market expansion as awareness, diagnostics, and treatment access improve across regions.
Explore Epidemiology, Emerging Therapies, and Competitive Landscape - Download Your Copy @ https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Current and Emerging Wet Age-Related Macular Degeneration Therapies
Wet Age-Related Macular Degeneration Marketed Drugs
1. EYLEA (Aflibercept) - Regeneron Pharmaceuticals
o Injectable VEGF inhibitor for Wet AMD, with ongoing Phase III trials testing extended dosing regimens.
2. BEOVU (Brolucizumab) - Novartis
o Anti-VEGF therapy offering dosing flexibility of up to 12 weeks.
3. VABYSMO (Faricimab) - Roche/Genentech
o First bispecific antibody targeting both Ang-2 and VEGF-A pathways.
These agents remain the backbone of Wet AMD treatment, with ongoing label expansions and post-marketing trials aimed at optimizing dosing and improving durability.
Gain Exclusive Access to Pipeline Therapies and Regulatory Trends - Get the Report Now @ https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Wet Age-Related Macular Degeneration Emerging Drugs in Pipeline
1. OPT-302 (Opthea Limited) - A VEGF-C/D inhibitor designed to complement anti-VEGF-A therapies.
2. KSI-501 (Kodiak Sciences) - Novel biologic providing extended VEGF inhibition for long-term efficacy.
3. RGX-314 (Regenxbio) - Gene therapy candidate administered via subretinal or suprachoroidal delivery.
4. EYP-1901 (EyePoint Pharmaceuticals) - Sustained-release anti-VEGF therapy under Phase II development.
5. ALK4290 (Alkahest) - Small molecule targeting inflammatory pathways in retinal diseases.
The late-stage pipeline reflects a paradigm shift from frequent intravitreal injections toward longer-acting biologics and gene therapies that aim to reduce treatment burden and improve compliance.
Recent Developments in Wet Age-Related Macular Degeneration Clinical Trials
• In April 2025, Kodiak Sciences announced positive Phase III results for Tarcocimab Tedromer and Tabirafusp Tedromer, demonstrating efficacy comparable to aflibercept in Wet AMD patients.
• Ongoing EMA and FDA reviews of emerging drugs are expected to accelerate therapeutic diversification by 2026.
• Regulatory frameworks in the EU5 and Japan (PMDA) are increasingly supportive of accelerated approvals for novel ophthalmology drugs.
• NICE approvals in the UK are likely to enhance early adoption of pipeline therapies post-commercial launch.
Wet Age-Related Macular Degeneration Market Dynamics and Trends
Wet Age-Related Macular Degeneration Market Drivers
• Rising global prevalence of Wet AMD due to aging demographics.
• Regulatory support for expedited approvals (EMA, FDA, PMDA, NICE).
• Increased R&D investment in ophthalmology therapeutics.
• Adoption of gene therapies and bispecific antibodies.
Wet Age-Related Macular Degeneration Market Barriers
• High treatment costs limiting access in low-income markets.
• Need for frequent intravitreal injections affecting compliance.
• Competition among biologics leading to pricing pressures.
• Complexity of long-term efficacy validation in real-world settings.
Wet Age-Related Macular Degeneration Competitive Landscape
DelveInsight's report profiles leading Wet AMD companies shaping the future market, including:
• Opthea Limited
• Outlook Therapeutics
• Kodiak Sciences
• Regenxbio
• Dobecure
• Gemini Therapeutics
• Huabo Biopharm
• Isarna Therapeutics
• IVERIC bio (formerly Ophthotech Corporation)
• Ribomic
• Curacle
• Bio-Thera Solutions
• AngioLab Inc.
• Alkahest
• Tyrogenex
• Iconic Therapeutics
• AiViva BioPharma
• Boehringer Ingelheim
• RemeGen
• And several others.
These players are investing heavily in clinical development, strategic collaborations, and geographic expansion to strengthen their position in the competitive Wet AMD therapeutics market.
Empower Your Strategic Decisions with In-Depth Wet AMD Market Intelligence - Get the Report Today @ https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Wet Age-Related Macular Degeneration Market Outlook (2020-2034)
DelveInsight projects that the Wet Age-Related Macular Degeneration market size will grow at a considerable CAGR across the 7MM during the study period. Growth will be fueled by:
• Increased patient population in the aging demographic.
• Launch of emerging therapies such as RGX-314, OPT-302, and KSI-501.
• Extended durability of treatment reducing patient burden.
• Broader reimbursement access through NICE, EMA, FDA, and PMDA-backed policies.
Key Takeaways from Wet Age-Related Macular Degeneration Market Report
• 40 million AMD cases across 7MM in 2023, with Wet AMD representing a significant portion.
• The US leads in prevalence (~14 million AMD cases), followed by Japan (~8 million) and Germany (~6 million).
• Pipeline therapies promise reduced injection frequency, improved efficacy, and novel mechanisms of action.
• Regulatory approvals from EMA, FDA, PMDA, and NICE will accelerate patient access to advanced treatments.
• Market leaders and emerging biotechs are actively shaping the therapeutic landscape with biologics, bispecific antibodies, and gene therapies.
Stay Ahead in the Wet AMD Market - Request a Sample of the Latest DelveInsight Study @ https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Wet Age-Related Macular Degeneration Market Report
• Coverage: 7MM (US, EU5, Japan)
• Study Period: 2020-2034
• Companies Covered: Opthea Limited, Outlook Therapeutics, Kodiak Sciences, Regenxbio, IVERIC bio, Ribomic, Curacle, Bio-Thera Solutions, AngioLab Inc., Alkahest, Tyrogenex, Boehringer Ingelheim, RemeGen, and others.
• Pipeline Therapies: RGX-314, Tarcocimab Tedromer, Aflibercept, KSI-301, EYP-1901, ALK4290, etc.
• Focus Areas: Epidemiology, market dynamics, therapies, regulatory approvals, unmet needs, reimbursement strategies, and SWOT analysis.
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Wet Age-Related Macular Degeneration Market Outlook 2034 - Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight here
News-ID: 4174405 • Views: …
More Releases from DelveInsight Business Research
Acute Ischemic Stroke Market Outlook 2034 - Clinical Trials, Market Size, Medica …
(Albany, USA) - DelveInsight has announced the release of its latest research publication, "Acute Ischemic Stroke Market Insights, Epidemiology, and Market Forecast 2034," providing a comprehensive analysis of the evolving treatment landscape, pipeline products, clinical trials, and regulatory milestones shaping the Acute Ischemic Stroke (AIS) treatment market across the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The report offers an in-depth understanding of disease epidemiology, market…
Global General Surgery Devices Market is expected to grow at a CAGR of 6.3% by 2 …
General Surgery Devices Market Overview
The Global General Surgery Devices Market is projected to grow at a CAGR of 6.34% from 2025 to 2032, driven by the rising burden of chronic diseases, increasing surgical interventions, and the adoption of robotic-assisted and minimally invasive techniques. Covering instruments such as handheld tools, electrosurgical devices, laparoscopic systems, wound closure products, and disposables, these devices play a critical role in diverse procedures, including orthopedic, cardiovascular,…
Intratumoral Cancer therapies Market Outlook 2034 - Clinical Trials, Market Size …
Intratumoral Cancer Market Summary
Intratumoral cancer therapies involve direct delivery into tumors, enabling localized targeting with minimal damage to surrounding tissue. Within the 7MM, non-melanoma cancers represent the largest share of cases and are expected to rise at ~2% annually, while in the US, breast cancer accounts for about 30% of cases with a growing incidence rate for intratumoral therapies. Currently, IMLYGIC is the only FDA-approved intratumoral therapy for melanoma, holding…
Bispecific and Trispecific Antibodies Market Projected to Experience Significant …
Bispecific antibodies represent an innovative class of therapies designed to address complex diseases by simultaneously binding two targets with a single molecule. Most currently approved bispecifics are for oncology, particularly multiple myeloma and diffuse large B-cell lymphoma (DLBCL). Beyond oncology, only HEMLIBRA and VABYSMO are approved for conditions such as hemophilia A, wet age-related macular degeneration, and diabetic macular edema, while KIMMTRAK is approved for uveal melanoma. The pipeline remains…
More Releases for Wet
Wet And Cold Appliance Market Size Analysis by Application, Type, and Region: Fo …
USA, New Jersey- According to Market Research Intellect, the global Wet And Cold Appliance market in the Internet, Communication and Technology category is projected to witness significant growth from 2025 to 2032. Market dynamics, technological advancements, and evolving consumer demand are expected to drive expansion during this period.
The wet and cold appliance market is expanding steadily, driven by changing consumer lifestyles, increasing urbanization, and rising demand for home automation. Appliances…
Semiconductor Electronic Wet Chemicals Market
Semiconductor Electronic Wet Chemicals Market Overview
Electronic wet chemicals are ultra-pure nature due to which they are extensively used in cleaning and etching application during semiconductor production and processing.
This report provides a deep insight into the global Semiconductor Electronic Wet Chemicals market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market…
Global Wet Suit Market Analysis (2025-2031)
LPI (LP Information) released the report titled "Global Wet Suit Market Growth (Status and Outlook) 2025-2031." This report provides a comprehensive analysis of the global Wet Suit landscape, with a focus on key trends related to product segmentation, company establishment, revenue and market share, recent developments, and merger and acquisition activities. Additionally, the report delves into the strategies of global leading companies, emphasizing their Wet Suit portfolios and capabilities, market…
Wet and Dry Vacuum Cleaner Market
The "Wet and Dry Vacuum Cleaner Market" is expected to reach USD xx.x billion by 2031, indicating a compound annual growth rate (CAGR) of xx.x percent from 2024 to 2031. The market was valued at USD xx.x billion In 2023.
Growing Demand and Growth Potential in the Global Wet and Dry Vacuum Cleaner Market, 2024-2031
Verified Market Research's most recent report, "Wet and Dry Vacuum Cleaner Market: Global Industry Trends, Share, Size,…
Wet Filtered Downdraught Workbench Market
Wet filtered downdraught workbench is the industry's leading solution for the collection of combustible metal dust which can safely removes combustible materials while complying with NFPA and OSHA combustible dust guidelines.
The global Wet Filtered Downdraught Workbench market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine…
Corn Wet-milling Market Corn Wet Milling Market Share, Size, Demand, Key Players …
Market Analysis and Insights of Global Corn Wet-milling Market
The corn wet-milling market is expected to witness market growth at a rate of 5.70% in the forecast period of 2022 to 2029. Data Bridge Market Research report on corn wet-milling market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market's growth. The growth in awareness globally is…
